Actinium-225

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Retrieved on: 
Thursday, March 28, 2024
Cancer, Receptor (biochemistry), Radionuclide, Patient, Neoplasm, PET, G&A, Worldwide Angel, Actinium-225, MTIC, Pancreatic cancer, Investment, Fifth, Therapy, Clinical trial, Safety

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
  • Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
    Cash, cash equivalents and short-term investments as of December 31, 2023, were $7.3 million.
  • R&D expenses for the fourth quarter of 2023 were $1.0 million compared to $2.1 million for the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 were $0.9 million, compared to $0.8 million for the fourth quarter of 2022.

Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress

Retrieved on: 
Wednesday, March 20, 2024
Actinium-225, Physics, Patient, Cancer

VALENCIA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile.

Key Points: 
  • VALENCIA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile.
  • Greg Moffitt, Nusano Director of Target Development, will provide an overview of the company’s proprietary radioisotope production platform on Sunday, March 24.
  • He will discuss Nusano’s plans to supply commercial-scale lutetium-177 beginning in early 2025 and to make the short-lived radioisotope, astatine-211, viable for therapeutic use.
  • “Nusano is bringing our commercial-scale, proprietary technology online to support cancer patients, stabilize supply chains and enable innovation,” said Greg Moffitt, Director of Target Development at Nusano.

RLS Radiopharmacies Partners with Eckert & Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

Retrieved on: 
Thursday, April 4, 2024
Oncology, Medical Devices, Health, Radiology, Pharmaceutical, Biotechnology, Gallium, Diagnosis, Radionuclide, Glomus tumor, Prostate cancer, USP, Half-life, Actinium-225, Partnership, Patient, Pharmacy, RLS, PET, Splenic infarction, Cancer, SDAX, Radiopharmaceutical, Investment, Cyclotron, ISO, Positron emission tomography, DSM-IV codes, Gelastic seizure, Medical imaging

Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.

Key Points: 
  • Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.
  • “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing.
  • This signifies a major leap forward in our commitment to advancing healthcare and improving patient outcomes through cutting-edge radiopharmaceuticals."
  • To date, RLS has installed Eckert & Ziegler’s GalliaPharm® generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June.

NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Hospitals, Health Technology, Radiology, Pharmaceutical, Biotechnology, Jefferies, Actinium-225, Radiopharmaceutical, Therapy, Cancer, NorthStar, CDMO, PET, Growth, Medical imaging

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.

Key Points: 
  • NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.
  • “2024 and the next several years are pivotal for NorthStar as we expand our capabilities in the rapidly growing radiopharmaceuticals industry,” said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • Our radiopharmaceutical R&D lab is busy with both PET diagnostics and therapeutics work where sponsors are experiencing useful results as they work to improve upon their formulations and processes.
  • Please reach out to your Jefferies representative to schedule.

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, Radiation, Prostate cancer, AstraZeneca, Patient, RCS, Acquisition, Cancer, Actinium-225, PSMA, Investment, Antibody, VWAP, Peptide, Medical imaging

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

Key Points: 
  • AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
  • These medicines deliver a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules.
  • The acquisition brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca.
  • RCs combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.

Retrieved on: 
Monday, March 25, 2024
Curium, FMI, Novartis, Eli Lilly, Face, FAP, Associate, Hospital, Bayer, Cancer, Actinium-225, Medicare, Radiopharmaceutical, Radio, Therapy, Eli Lilly and Company, Government

NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that.

Key Points: 
  • This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead.
  • NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide.
  • With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade.
  • Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade.

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

Retrieved on: 
Monday, March 11, 2024
Actinium, Synthase, NCI, Recycling, Actinium-225, International, CRADA, DNA, Research, Thorium, Linear energy transfer, Investment, Cyclotron, DOE, Medicine

Actinium's intellectual property portfolio relating to its cyclotron-based production method includes 5 issued U.S. patents and 49 issued international patents as well as significant technical know-how.

Key Points: 
  • Actinium's intellectual property portfolio relating to its cyclotron-based production method includes 5 issued U.S. patents and 49 issued international patents as well as significant technical know-how.
  • The DOE has stated that it is exploring the generation of new thorium cows and production via a cyclotron.
  • Based on our experience to date, we expect to be able to produce material with high radiochemical purity and at yields not possible with thorium-cow based methods.
  • This has the potential to further establish Actinium as a leader in alpha-particle therapies and remain at the forefront of innovation while addressing a significant and rapidly growing addressable patient population."

Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration

Retrieved on: 
Monday, March 11, 2024
Actinium-225, Biotechnology, Drug development, Growth, Foot, Radionuclide, Risk, Radiochemistry, Physics, Health, Patient, Cancer

“Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.

Key Points: 
  • “Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.
  • We expect to begin producing non-carrier added lutetium-177 in Q1 2025, followed by actinium-225 in the second half of the year,” said Chris Lowe, CEO of Nusano.
  • Nusano is working to supply the fight against cancer by combining the company’s expertise in physics and radiochemistry to meet the medical isotope needs of today and enable the cancer radiotherapeutics of tomorrow.
  • Anna Goldberg, director of Radiochemistry and Production Operations for Nusano, added, “Nusano’s radiochemistry team is a world-class group of experts working at the forefront of their field.

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Retrieved on: 
Tuesday, March 5, 2024
Neoplasm, Actinium-225, SPECT, MD, Radionuclide, Therapy, Receptor (biochemistry), Patient, Radiopharmaceutical, Pancreatic cancer, Cancer, Medical imaging

This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.

Key Points: 
  • This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.
  • Two of the most commercially successful radiopharmaceuticals, Pluvicto® and Lutathera™, use the therapeutic radioisotope Lutetium-177 (Lu-177).
  • Monopar collected a sequential SPECT imaging time-series utilizing MNPR-101 conjugated to Lu-177 (MNPR-101-Lu) in a uPAR-expressing human pancreatic cancer xenograft model.
  • “These data further support the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients with uPAR-positive tumors.”

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

Retrieved on: 
Monday, March 4, 2024
Acquisition, Pharmacy, TMS, TRIUMF, Actinium-225, Chemistry, Isotope, Sale, TLX, Physics, ASX, Clinical trial, Science, Ultra, Research, Partnership, Medical imaging

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

Key Points: 
  • MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
  • Telix is currently validating multiple production locations of large-scale 89Zr production in the United States (U.S.) using the QIS system and select manufacturing and pharmacy partners.
  • ARTMS and Telix have been collaborating since 20202 to evaluate the potential of higher curie-scale (Ci) production of Illuccix®.
  • As part of the acquisition, Telix will also acquire the benefit of ARTMS’s production facility and clean rooms, located in Burnaby, BC (Canada).